Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001172661-25-000872
Filing Date
2025-02-14
Accepted
2025-02-14 08:40:11
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 9659
  Complete submission text file 0001172661-25-000872.txt   11592
Mailing Address 5858 HORTON STREET #455 EMERYVILLE CA 94608
Business Address 5858 HORTON STREET #455 EMERYVILLE CA 94608 5105052680
4D Molecular Therapeutics, Inc. (Subject) CIK: 0001650648 (see all company filings)

EIN.: 473506994 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-91921 | Film No.: 25623514
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 200 GREENWICH AVENUE 3RD FLOOR GREENWICH CT 06830
Business Address 200 GREENWICH AVENUE 3RD FLOOR GREENWICH CT 06830 2034090812
Deep Track Capital, LP (Filed by) CIK: 0001856083 (see all company filings)

EIN.: 853360885 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A